Trials / Completed
CompletedNCT01978314
FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.
A Single-Center Prospective Study Evaluating the FAST Measured Glomerular Filtration Rate (mGFR) Test™ in Adults With Preserved Kidney Function and Impaired Kidney Function With Comparison to Iohexol Clearance Methods
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- FAST BioMedical · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a single site study designed to evaluate the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of chronic kidney disease (CKD), and patients with acute kidney injury (AKI).
Detailed description
A rapid and accurate measurement of glomerular filtration rate (GFR) is important in acute kidney injury (AKI) and chronic kidney disease (CKD) for assessment of impairment, diagnosis, and prompt treatment. FAST BioMedical is an emerging technology company whose mission is to quantify clinically meaning ful physiological parameters that have been difficult or impossible to measure. GFR is the most clinically relevant metric for understanding renal function, as it is the rate by which the kidney is able to filter waste products in the bloodstream. The FAST mGFR is for direct measurement of GFR that relies on reading the ratio of fluorescent markers attached to different size dextran molecules introduced into the bloodstream. The test is intended as an adjunct to current methods utilized to assess kidney function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | 75 mg / 6 mL VFI™ | Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached. |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-11-07
- Last updated
- 2017-12-12
- Results posted
- 2017-12-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01978314. Inclusion in this directory is not an endorsement.